Differential distribution of actual and surrogate oncotype DX recurrence scores in breast cancer patients by age, menopausal status, race, and body mass index.
Age
BMI
Breast cancer
Epidemiology
Menopause
Obesity
Oncotype
Race
Recurrence Models
Journal
Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
29
04
2023
accepted:
26
06
2023
medline:
29
8
2023
pubmed:
16
7
2023
entrez:
15
7
2023
Statut:
ppublish
Résumé
The Oncotype DX Recurrence Score (RS) is a widely used prognostic tool for estrogen receptor-positive breast cancer patients. Multiple surrogate models can predict RS with good accuracy. In this study we aimed to determine whether the RS and two surrogate indices were differentially distributed by age, menopausal status, race, and body mass index (BMI). 516 breast cancer cases treated at a single institution were analyzed. Epidemiologic data, RS, tumor size, grade, and biomarker data were abstracted. Breast Cancer Prognostic Score (BCPS) and modified Magee equation 2 were used to calculate surrogate RS. Patients were stratified into different groups based on age, menopausal status, race, BMI, or a combination of strata. Mean and standard deviation were calculated for each group/subgroup. Age below median (< 63) was associated with higher RS, especially in obese and Black patients. RS was also higher in obese and Black patients in the premenopausal subgroup. Black patients had a higher RS compared to White women in the premenopausal and non-obese subgroups. BMI < 30 was associated with higher RS, especially in older, postmenopausal, and Black patients. Some of these observations were replicated by the two surrogate models. The surrogate recurrence scores were higher in the younger age group, in non-obese older/postmenopausal women, and in younger/premenopausal obese individuals. Higher RS was observed in younger and premenopausal breast cancer patients, especially among the Black and obese subgroups, and in non-obese patients, especially among Black and older/postmenopausal women, suggesting more aggressive disease in these subgroups. Some statistical differences could be replicated by both surrogate models, suggesting that they may have utility in breast cancer epidemiology studies that do not have access to Oncotype DX RS or patient outcome data.
Identifiants
pubmed: 37453958
doi: 10.1007/s10549-023-07025-8
pii: 10.1007/s10549-023-07025-8
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
447-460Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Giaquinto AN, Miller KD, Tossas KY, Winn RA, Jemal A, Siegel RL (2022) Cancer statistics for African American/Black people 2022. CA Cancer J Clin 72(3):202–229. https://doi.org/10.3322/caac.21718
doi: 10.3322/caac.21718
pubmed: 35143040
Lord SJ, Marinovich ML, Patterson JA et al (2012) Incidence of metastatic breast cancer in an Australian population-based cohort of women with non-metastatic breast cancer at diagnosis. Med J Aust 196(11):688–692. https://doi.org/10.5694/mja12.10026
doi: 10.5694/mja12.10026
pubmed: 22708766
Chen HL, Zhou MQ, Tian W, Meng KX, He HF (2016) Effect of age on breast cancer patient prognoses: a population-based study using the SEER 18 database. PLoS ONE 11(10):e0165409. https://doi.org/10.1371/journal.pone.0165409
doi: 10.1371/journal.pone.0165409
pubmed: 27798652
pmcid: 5087840
Partridge AH, Hughes ME, Warner ET et al (2016) Subtype-dependent relationship between young age at diagnosis and breast cancer survival. J Clin Oncol 34(27):3308–3314. https://doi.org/10.1200/JCO.2015.65.8013
doi: 10.1200/JCO.2015.65.8013
pubmed: 27480155
Cheng R, Kong X, Wang X, Fang Y, Wang J (2020) Oncotype DX breast recurrence score distribution and chemotherapy benefit among women of different age groups with HR-positive, HER2-negative, node-negative breast cancer in the SEER database. Front Oncol. 10:1583. https://doi.org/10.3389/fonc.2020.01583
doi: 10.3389/fonc.2020.01583
pubmed: 33194568
pmcid: 7663955
Vu Hong T, Nguyen Ba D, Skoog L, Ta Thanh V, Tani E (2019) Breast cancer survival defined by biological receptor and menopausal status in Vietnamese women. Cancer Control 26(1):1073274819865279. https://doi.org/10.1177/1073274819865279
doi: 10.1177/1073274819865279
pubmed: 31343899
pmcid: 6659192
Lao C, Elwood M, Kuper-Hommel M, Campbell I, Lawrenson R (2021) Impact of menopausal status on risk of metastatic recurrence of breast cancer. Menopause 28(10):1085–1092. https://doi.org/10.1097/GME.0000000000001817
doi: 10.1097/GME.0000000000001817
pubmed: 34260475
Protani M, Coory M, Martin JH (2010) Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat 123(3):627–635. https://doi.org/10.1007/s10549-010-0990-0
doi: 10.1007/s10549-010-0990-0
pubmed: 20571870
Niraula S, Ocana A, Ennis M, Goodwin PJ (2012) Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-analysis. Breast Cancer Res Treat 134(2):769–781. https://doi.org/10.1007/s10549-012-2073-x
doi: 10.1007/s10549-012-2073-x
pubmed: 22562122
Sparano JA, Wang M, Zhao F et al (2012) Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial. J Natl Cancer Inst 104(5):406–414. https://doi.org/10.1093/jnci/djr543
doi: 10.1093/jnci/djr543
pubmed: 22250182
pmcid: 3295746
Luís C, Dias J, Firmino-Machado J et al (2023) A retrospective study in tumour characteristics and clinical outcomes of overweight and obese women with breast cancer. Breast Cancer Res Treat 198(1):89–101. https://doi.org/10.1007/s10549-022-06836-5
doi: 10.1007/s10549-022-06836-5
pubmed: 36576677
Paik S, Shak S, Tang G et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27):2817–2826. https://doi.org/10.1056/NEJMoa041588
doi: 10.1056/NEJMoa041588
pubmed: 15591335
Namuche F, Ruiz RE, Morante Cruz ZD et al (2018) Oncotype Dx results in patients £ 40 years: does age matter? New insights. Ann Oncol 29(Suppl 8):67–68
doi: 10.1093/annonc/mdy270.206
Kalinsky K, Barlow WE, Gralow JR et al (2021) 21-Gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med 385(25):2336–2347. https://doi.org/10.1056/NEJMoa2108873
doi: 10.1056/NEJMoa2108873
pubmed: 34914339
pmcid: 9096864
Zhang S, Fitzsimmons KC, Hurvitz SA (2022) Oncotype DX recurrence score in premenopausal women. Ther Adv Med Oncol. 14:17588359221081076. https://doi.org/10.1177/17588359221081077
doi: 10.1177/17588359221081077
pubmed: 35295864
pmcid: 8918761
Carr DN, Vera N, Sun W et al (2015) Menopausal status does not predict oncotype DX recurrence score. J Surg Res 198(1):27–33. https://doi.org/10.1016/j.jss.2015.05.034
doi: 10.1016/j.jss.2015.05.034
pubmed: 26095420
Holowatyj AN, Cote ML, Ruterbusch JJ et al (2018) Racial differences in 21-gene recurrence scores among patients with hormone receptor-positive, node-negative breast cancer [published correction appears in J Clin Oncol. 2018 Apr 1;36(10):1054]. J Clin Oncol. 36(7):652–658. https://doi.org/10.1200/JCO.2017.74.5448
doi: 10.1200/JCO.2017.74.5448
pubmed: 29341832
pmcid: 6366808
Han Y, Miao ZF, Lian M, Peterson LL, Colditz GA, Liu Y (2020) Racial and ethnic disparities in 21-gene recurrence scores, chemotherapy, and survival among women with hormone receptor-positive, node-negative breast cancer. Breast Cancer Res Treat 184(3):915–925. https://doi.org/10.1007/s10549-020-05902-0
doi: 10.1007/s10549-020-05902-0
pubmed: 32929567
pmcid: 7658025
Lund MJ, Mosunjac M, Davis KM et al (2012) 21-Gene recurrence scores: racial differences in testing, scores, treatment, and outcome. Cancer 118(3):788–796. https://doi.org/10.1002/cncr.26180
doi: 10.1002/cncr.26180
pubmed: 21720988
Collin LJ, Yan M, Jiang R et al (2019) Oncotype DX recurrence score implications for disparities in chemotherapy and breast cancer mortality in Georgia. NPJ Breast Cancer 5:32. https://doi.org/10.1038/s41523-019-0129-3
doi: 10.1038/s41523-019-0129-3
pubmed: 31583272
pmcid: 6763428
Hoskins KF, Danciu OC, Ko NY, Calip GS (2021) Association of race/ethnicity and the 21-gene recurrence score with breast cancer-specific mortality among US women. JAMA Oncol 7(3):370–378. https://doi.org/10.1001/jamaoncol.2020.7320
doi: 10.1001/jamaoncol.2020.7320
pubmed: 33475714
Moore J, Wang F, Pal T et al (2022) Oncotype DX risk recurrence score and total mortality for early-stage breast cancer by race/ethnicity. Cancer Epidemiol Biomarkers Prev 31(4):821–830. https://doi.org/10.1158/1055-9965.EPI-21-0929
doi: 10.1158/1055-9965.EPI-21-0929
pubmed: 35064066
pmcid: 8983577
Albain KS, Gray RJ, Makower DF et al (2021) Race, ethnicity, and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer in the randomized TAILORx trial. J Natl Cancer Inst 113(4):390–399. https://doi.org/10.1093/jnci/djaa148
doi: 10.1093/jnci/djaa148
pubmed: 32986828
Tong Y, Gao W, Wu J et al (2021) Comprehensive association analysis of 21-gene recurrence score and obesity in chinese breast cancer patients. Front Oncol. 11:619840. https://doi.org/10.3389/fonc.2021.619840
doi: 10.3389/fonc.2021.619840
pubmed: 33842323
pmcid: 8032994
Lee J, Kim H, Bae SJ et al (2022) Association of body mass index with 21-gene recurrence score among women with estrogen receptor-positive, ERBB2-negative breast cancer. JAMA Netw Open 5(11):e2243935. https://doi.org/10.1001/jamanetworkopen.2022.43935
doi: 10.1001/jamanetworkopen.2022.43935
pubmed: 36441548
pmcid: 9706366
Geradts J, Bean SM, Bentley RC, Barry WT (2010) The oncotype DX recurrence score is correlated with a composite index including routinely reported pathobiologic features. Cancer Invest 28(9):969–977. https://doi.org/10.3109/07357907.2010.512600
doi: 10.3109/07357907.2010.512600
pubmed: 20873988
Klein ME, Dabbs DJ, Shuai Y et al (2013) Prediction of the oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis. Mod Pathol 26(5):658–664. https://doi.org/10.1038/modpathol.2013.36
doi: 10.1038/modpathol.2013.36
pubmed: 23503643
pmcid: 3647116
Turner BM, Skinner KA, Tang P et al (2015) Use of modified Magee equations and histologic criteria to predict the oncotype DX recurrence score. Mod Pathol 28(7):921–931. https://doi.org/10.1038/modpathol.2015.50
doi: 10.1038/modpathol.2015.50
pubmed: 25932962
Mohamed A, Kousar A, Wong J, Vohra N, Muzaffar M, Geradts J (2022) Pathobiologic stratification of oncotype DX recurrence scores and comparative validation of 3 surrogate models. Arch Pathol Lab Med 146(10):1258–1267. https://doi.org/10.5858/arpa.2021-0367-OA
doi: 10.5858/arpa.2021-0367-OA
pubmed: 35119458
Allred DC (2010) Issues and updates: evaluating estrogen receptor-alpha, progesterone receptor, and HER2 in breast cancer. Mod Pathol 23(Suppl 2):S52–S59. https://doi.org/10.1038/modpathol.2010.55
doi: 10.1038/modpathol.2010.55
pubmed: 20436503
Cress RD, Chen YS, Morris CR, Chew H, Kizer KW (2016) Underutilization of gene expression profiling for early-stage breast cancer in California. Cancer Causes Control 27(6):721–727. https://doi.org/10.1007/s10552-016-0743-4
doi: 10.1007/s10552-016-0743-4
pubmed: 27097910
pmcid: 4871729
Orucevic A, Heidel RE, Bell JL (2016) Utilization and impact of 21-gene recurrence score assay for breast cancer in clinical practice across the United States: lessons learned from the 2010 to 2012 national cancer data base analysis. Breast Cancer Res Treat 157(3):427–435. https://doi.org/10.1007/s10549-016-3833-9
doi: 10.1007/s10549-016-3833-9
pubmed: 27206678
pmcid: 4903105
Press DJ, Ibraheem A, Dolan ME, Goss KH, Conzen S, Huo D (2018) Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test results. Breast Cancer Res Treat 168(1):207–220. https://doi.org/10.1007/s10549-017-4587-8
doi: 10.1007/s10549-017-4587-8
pubmed: 29181717
Ko NY, Qureshi MM, Oladeru OT et al (2020) Racial differences in genomic testing and receipt of endocrine therapy in early-stage breast cancer. Breast Cancer Res Treat 184(3):849–859. https://doi.org/10.1007/s10549-020-05888-9
doi: 10.1007/s10549-020-05888-9
pubmed: 32888137
Guth AA, Fineberg S, Fei K, Franco R, Bickell NA (2013) Utilization of oncotype DX in an inner city population: race or place? Int J Breast Cancer. 2013:653805. https://doi.org/10.1155/2013/653805
doi: 10.1155/2013/653805
pubmed: 24455283
pmcid: 3878389
Davis BA, Aminawung JA, Abu-Khalaf MM et al (2017) Racial and ethnic disparities in oncotype DX test receipt in a statewide population-based study. J Natl Compr Canc Netw 15(3):346–354. https://doi.org/10.6004/jnccn.2017.0034
doi: 10.6004/jnccn.2017.0034
pubmed: 28275035
Roberts MC, Weinberger M, Dusetzina SB et al (2016) Racial variation in the uptake of oncotype DX testing for early-stage breast cancer. J Clin Oncol 34(2):130–138. https://doi.org/10.1200/JCO.2015.63.2489
doi: 10.1200/JCO.2015.63.2489
pubmed: 26598755
Allott EH, Geradts J, Cohen SM et al (2018) Frequency of breast cancer subtypes among African American women in the AMBER consortium. Breast Cancer Res 20(1):12. https://doi.org/10.1186/s13058-018-0939-5
doi: 10.1186/s13058-018-0939-5
pubmed: 29409530
pmcid: 5801839
Polley MY, Leung SC, McShane LM et al (2013) An international Ki67 reproducibility study. J Natl Cancer Inst 105(24):1897–1906. https://doi.org/10.1093/jnci/djt306
doi: 10.1093/jnci/djt306
pubmed: 24203987
pmcid: 3888090
Beadle BM, Woodward WA, Buchholz TA (2011) The impact of age on outcome in early-stage breast cancer. Semin Radiat Oncol 21(1):26–34. https://doi.org/10.1016/j.semradonc.2010.09.001
doi: 10.1016/j.semradonc.2010.09.001
pubmed: 21134651
pmcid: 3041510